

POCKET NO.: CELL-0296

PATENT

PUT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Helene Margaret Finney, et al.

Confirmation No.: Not Yet Assigned

Application No.: 10/533,003

Group Art Unit: Not Yet Assigned

Filing Date: April 28, 2005

Examiner: Not Yet Assigned

For: CHIMERIC CYTOPLASMIC SIGNALLING MOLECULES

DATE OF DEPOSIT: July 18, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,

VA 22313-1459

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

	the above identified application as set forth in § 1.491, before the mailing date
	of a first Office Action on the merits of the above-identified application, or
	before the mailing date of a first Office Action after the filing of request for
	continued examination under § 1.114, no additional fee is required.
	In accordance with § 1.97(c), this Information Disclosure Statement is being
	filed after the period set forth in § 1.97(b) above but before the mailing date of
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or
	before an action that otherwise closes prosecution in the application, therefore:
	Certification in Accordance with § 1.97(e) is attached; or
	The fee of $$180.00$ as set forth in § 1.17(p) is attached.
	In accordance with § 1.97(d), this Information Disclosure Statement is being
	filed after the mailing date of either a Final Action under § 1.113 or a Notice
	of Allowance under § 1.311 but before, or simultaneously with, the payment
	of the Issue Fee, therefore included are: Certification in Accordance with §
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).
\boxtimes	Copies of reference numbers 1 - 42 listed on the attached Form PTO-1449 are
	enclosed herewith.
	Copies of reference numbers - on the attached Form PTO 1449
	are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).
	Copies of references - are not being submitted because
	they were previously cited by or submitted to the U.S. Patent and
	Trademark Office in patent application number , filed for
	which a claim for priority under 35 U.S.C. § 120 has been made in the
	instant application.

DOCI	KET NO.: CELL-0296	3 -	PATENT
	The relevance of those listed referent follows:	ces which are not in the English	language is as
	There are no listed references which a	are not in the English language.	
	Please charge any deficiency or cred	it any overpayment to Deposit Ac	count No. 23-
3050.	This form is submitted in duplicate.		
Date:	July 15, 2005	Jane Deugloso Jane E. Inglese	
		Registration No. 48,444	
wooi	DCOCK WASHBURN LLP		

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW

Form PTO-144 List of Patent and Cited by Ap (Use several sheet U.S. Department Patent and Trade	Publications pplicant s if necessary) of Commerce	Docket No CELL-029 PA524-US Applicant Helene M Filing Dat April 28, 2 Confirmat Not Yet A	96/ Sw01 argaret Finney, e 2005 ion No.	Application No. 10/533,003 et al. Group Not Yet Assigned			
OTHER DO	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
I I							
2 Arc							
cor							
5 Car							
	Eshar, Z., et al., "Functional expression of chimeric receptor genes in human T cells," J. of Immunol. Methods, 2001, 248, 67-76						
sig 279	Finney, H.M., et al., "Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product," <i>J. of Immunol.</i> , 1998 , <i>161</i> , 2791-2797						
l l	Hombach, A., et al., "Tumor-specific T cell activation by recombinant						
req	immunoreceptors: CD3ξ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined DC28/CD3ξ signaling receptor molecule," J. of Immunol., 2001, 167, 6123-6131						
EXAMINER							

List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office Filing Date April 28, 2005 Confirmation No. Not Yet Assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) 11 Hutloff, A., et al., "ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28," Nature, 1999, 397, 263-266 12 Kjaergaard, J., et al., "Therapeutic efficacy of OX-40 receptor antibody depends of tumor immunogenicity and anatomic site of tumor growth," Cancer Res., 2000, 60 5514-5521 13 Kuwana, Y., et al., "Expression of chimeric receptor composed of immunoglobuling derived V resions and T-cell receptor-derived C regions," Biochem. & Biophys. Reserved. Commun., 1987, 149(3), 960-968 14 Latza, U., et al., "The human OX40 homolog: cDNA structure, expression and					
Patent and Trademark Office Patent and Trademark Office April 28, 2005 Not Yet Assigned					
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) 11 Hutloff, A., et al., "ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28," Nature, 1999, 397, 263-266 12 Kjaergaard, J., et al., "Therapeutic efficacy of OX-40 receptor antibody depends o tumor immunogenicity and anatomic site of tumor growth," Cancer Res., 2000, 66 5514-5521 13 Kuwana, Y., et al., "Expression of chimeric receptor composed of immunoglobuling derived V resions and T-cell receptor-derived C regions," Biochem. & Biophys. Research Commun., 1987, 149(3), 960-968 14 Latza, U., et al., "The human OX40 homolog: cDNA structure, expression and					
 Hutloff, A., et al., "ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28," Nature, 1999, 397, 263-266 Kjaergaard, J., et al., "Therapeutic efficacy of OX-40 receptor antibody depends o tumor immunogenicity and anatomic site of tumor growth," Cancer Res., 2000, 66 5514-5521 Kuwana, Y., et al., "Expression of chimeric receptor composed of immunoglobuling derived V resions and T-cell receptor-derived C regions," Biochem. & Biophys. Research Commun., 1987, 149(3), 960-968 Latza, U., et al., "The human OX40 homolog: cDNA structure, expression and 					
functionally related to CD28," Nature, 1999, 397, 263-266 12 Kjaergaard, J., et al., "Therapeutic efficacy of OX-40 receptor antibody depends o tumor immunogenicity and anatomic site of tumor growth," Cancer Res., 2000, 66 5514-5521 13 Kuwana, Y., et al., "Expression of chimeric receptor composed of immunoglobulin derived V resions and T-cell receptor-derived C regions," Biochem. & Biophys. Recommun., 1987, 149(3), 960-968 14 Latza, U., et al., "The human OX40 homolog: cDNA structure, expression and					
tumor immunogenicity and anatomic site of tumor growth," Cancer Res., 2000, 60 5514-5521 13 Kuwana, Y., et al., "Expression of chimeric receptor composed of immunoglobuling derived V resions and T-cell receptor-derived C regions," Biochem. & Biophys. Research Commun., 1987, 149(3), 960-968 14 Latza, U., et al., "The human OX40 homolog: cDNA structure, expression and					
derived V resions and T-cell receptor-derived C regions," Biochem. & Biophys. Re Commun., 1987, 149(3), 960-968 14 Latza, U., et al., "The human OX40 homolog: cDNA structure, expression and					
14 Latza, U., et al., "The human OX40 homolog: cDNA structure, expression and					
					16 Miller, D.G., et al., "Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection," Mol. & Cell. Biol., 1990, 10(8), 4239-4242
17 Moingeon, P., et al., "Human natural killer cells and mature T lymphocytes express identical CD3 ξ subunits as defined by cDNA cloning and sequence analysis," Eur. J. of Immunol., 1990, 20, 1741-1745					
Parry, R.V., et al., "CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bc1-xI and IL-2 expression in primary human CD4 T lymphocytes," J. of Immunol., Baltimore, 2003, 171(1), 166-174					
19 Reth, M., "Antigen receptor tail clue," Nature, 1989, 338, 383-384					
20 Rogers, P.R., et al., "OX40 promotes Bc1-xL and Bc1-2 expression and is essential for long-term survival of CD4 T cells," <i>Immunity, US</i> , 2001, 15(3), 445-455					
EXAMINER DATE CONSIDERED					

Form PTO-1449 Modified List of Patent and Publications			Docket No CELL-029 PA524-US	06/	Application No. 10/533,003	
(Use sev	ited b	by Applicant sheets if necessary)	Applicant Helene Margaret Finney, et al.			
U.S. Department of Commerce Patent and Trademark Office			Filing Dat April 28, 2		Group Not Yet Assigned	
Confirmation No. Not Yet Assigned						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
	Romeo, C., et al., "Activation of immune system effector function by T-cell or Fc receptor intracellular domains," <u>Cold Spring Harbour Symposia on Quantitative Biology, Vol. LVII</u> , 1992, 117-125					
	22	cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses," J. of Exper. Med., Tokyo, 1997, 186(1), 47-55				
	23	Weiss, A., et al., "Signa 76, 26-274	al transduction	on by lymphoc	yte antigen receptors," Cell, 1994,	
	24				romosomal localization of the molecular CD3 complex," PNAS,	
EXAMINER		<u></u>		DATE CONS	SIDERED	

Docket No. Application No. Form PTO-1449 Modified CELL-0296/ 10/533,003 PA524-USw01 List of Patent and Publications Cited by Applicant Applicant Helene Margaret Finney, et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group Patent and Trademark Office April 28, 2005 Not Yet Assigned Confirmation No. Not Yet Assigned FOREIGN PATENT DOCUMENTS Examiner Translation Initial Document No. Date Country **YES** NO 25 WO 88/04924 A1 07/14/88 **PCT** 26 WO 90/09782 A1 09/07/90 **PCT PCT** WO 91/05545 A1 05/02/91 27 **PCT** WO 91/05546 A1 05/02/91 28 **PCT** 29 WO 93/19738 A1 10/14/93 **PCT** 09/15/94 30 WO 94/20073 A1 PCT WO 94/22429 A1 10/13/94 31 PCT **32** WO 96/10038 A1 -04/04/96 **PCT** 33 WO 96/23814 A1 ² 08/08/96 **PCT** 08/15/96 WO 96/24671 A1 34 PCT X abstract 05/22/97 WO 97/18185 A1 35 PCT 07/03/97 36 WO 97/23613 A3 **PCT** WO 97/25329 A1 07/17/97 37 PCT 08/21/97 WO 97/30170 A1 38 PCT 39 WO 97/31934 A3° 09/04/97

DATE CONSIDERED

EXAMINER

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office			Docket No. CELL-0296/ PA524-USw01 Applicant Helene Margaret Fin Filing Date April 28, 2005 Confirmation No. Not Yet Assigned	Application No. 10/533,003 nney, et al. Group Not Yet Assigned			
	FOREIGN PAT			ENT DOCUMENTS			
Examiner		D	TO A	G			slation
Initial	40	Document No. WO 99/00494 A3 '	Date 01/07/99	Country PCT		YES	NO
				PCT			
	41	WO 99/57268 A1 '	11/11/99	PCT			
	42	WO 02/33101 A1	04/25/02	PCI			
						··	
EXAMINER				DATE CONSIDER	RED		